Unlocking Treg potential: Overcoming key barriers in regulatory T cell therapy development with LentiBOOST transduction enhancer

Engineered regulatory T cells (Tregs) hold transformative promise for autoimmune disease, transplantation, and chronic inflammation but inefficient lentiviral gene delivery remains a critical manufacturing bottleneck. Discover how Revvity's LentiBOOST™ transduction enhancer is helping cell therapy developers overcome the key barriers standing between Treg biology and scalable, reproducible manufacturing.

Inside this white paper, you'll find:

• Why Tregs are notoriously resistant to standard lentiviral transduction and what that means for your program
• Published data showing how LentiBOOST enhancer supports consistent transduction efficiency while preserving FOXP3 expression and Treg phenotypic stability
• Real-world applications across antigen-specific TCR engineering, CAR-Treg development, and mechanistic studies
• How LentiBOOST enhancer helps control vector copy number in line with regulatory guidance, reducing risk without sacrificing yield
• Why reproducible gene delivery can be the difference between program success and failure when working with scarce patient-derived cells

Download your copy of the white paper and take the next step towards more efficient, scalable Treg manufacturing.

LentiBOOST Pharma-Grade technology: For research use only. Not for use in diagnostic procedures. LentiBOOST GMP Grade technology: Not for diagnostic use. Other applications must be authorized by a license from Revvity.